Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05182658
What this trial is testing

Empagliflozin in Hypertrophic Cardiomyopathy

Who this might be right for
Hypertrophic CardiomyopathyHeart Failure
National Institute of Cardiology, Warsaw, Poland 250
Not applicableStudy completedNCT03939624
What this trial is testing

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Who this might be right for
Type2 DiabetesMyocardial InfarctionIschemic Stroke+3 more
Canadian Network for Observational Drug Effect Studies, CNODES 419,734
Post-approval studies (Phase 4)UnknownNCT05966818
What this trial is testing

Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.

Who this might be right for
Nephrotic Syndrome
Ain Shams University 90
Not applicableNot Yet RecruitingNCT07770737
What this trial is testing

Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)Cardiovascular DiseasesStage B Heart Failure
Dongtan Sacred Heart Hospital 100
Not applicableStudy completedNCT06000722
What this trial is testing

SGLT-i Use in Diabetic Foot Ulcer Disease

Who this might be right for
Diabetic Foot Ulcer
University of Leicester 21
Not applicableUnknownNCT04961931
What this trial is testing

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Who this might be right for
Chronic Kidney Disease stage3
Medical University of Lodz 45
Large-scale testing (Phase 3)UnknownNCT05505994
What this trial is testing

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Who this might be right for
Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism Disorders+2 more
Daewoong Pharmaceutical Co. LTD. 340
Not applicableUnknownNCT05477017
What this trial is testing

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Who this might be right for
Type2Diabetes
University of Milan 800
Large-scale testing (Phase 3)Not Yet RecruitingNCT07417306
What this trial is testing

HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Who this might be right for
Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 912
Testing effectiveness (Phase 2)WithdrawnNCT04143581
What this trial is testing

SGLT2 Inhibitors in Glomerular Hyperfiltration

Who this might be right for
ObesityNon-diabetic Chronic Kidney Disease
Mario Negri Institute for Pharmacological Research
Post-approval studies (Phase 4)Study completedNCT04238702
What this trial is testing

Renohemodynamic Effects of Combined empagliflOzin and LosARtan

Who this might be right for
Diabetes Mellitus, Type 2Diabetic Kidney Disease
Amsterdam UMC, location VUmc 24
Not applicableUnknownNCT06097585
What this trial is testing

Gliflozins on HF in Regurgitant Rheumatic Heart

Who this might be right for
Rheumatic Heart DiseaseHeart Failure
Assiut University 150
Not applicableUnknownNCT05333159
What this trial is testing

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Who this might be right for
Coronary Artery DiseaseDiabete Mellitus
Beijing Anzhen Hospital 1,424
Not applicableStudy completedNCT06951737
What this trial is testing

Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Who this might be right for
Diabetes MellitusAtrial Fibrillation (AF)
Bursa Postgraduate Hospital 120
Post-approval studies (Phase 4)Study completedNCT03030222
What this trial is testing

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Who this might be right for
Heart Failure
Saint Luke's Health System 65
Large-scale testing (Phase 3)Study completedNCT02729766
What this trial is testing

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Who this might be right for
Inappropriate ADH Syndrome
University Hospital, Basel, Switzerland 15
Early research (Phase 1)Looking for participantsNCT05960656
What this trial is testing

SGLTi, Hepatic Glucose Production and Ketogenesis

Who this might be right for
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio 30
Post-approval studies (Phase 4)Not Yet RecruitingNCT06922656
What this trial is testing

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

Who this might be right for
Type 1 Diabetes
Dasman Diabetes Institute 60
Post-approval studies (Phase 4)Study completedNCT05857085
What this trial is testing

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Who this might be right for
Endothelial DysfunctionDiabetes Mellitus, Type 1Biomarkers+7 more
General and Teaching Hospital Celje 90
Testing effectiveness (Phase 2)Looking for participantsNCT06913647
What this trial is testing

Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

Who this might be right for
ESRDCKD (Chronic Kidney Disease) Stage 5D
McGill University Health Centre/Research Institute of the McGill University Health Centre 30
Next Page